Kraig Biocraft Laboratories Inc (KBLB)

[arachnodude]

***BALANCED PERSPECTIVE FOR NOTICE OF EFFECTIVENESS***

While this could lead to the issuance of new shares, it’s essential to understand the strategic context:

Capital for Growth: Issuing new shares can provide the necessary funds for advancing research, development, and commercialization efforts, especially for groundbreaking technologies like Spider Silk.

Strategic Dilution: Any dilution is likely a strategic move to secure funding essential for the company’s growth and long-term success, not an indiscriminate action. (Essentially what KBLB is noted for over the past 18 years).

Regulatory Approval: The effectiveness notice is a regulatory requirement for transparency and legal compliance in public offerings.

Understanding the broader context of such moves, especially for a company in a high-growth phase, is crucial for a balanced perspective.